1. 1 Top-Down vs Step-Up Trial Endoscopic Substudy: Mucosal Healing Patients, % 88 71 47 30 P<0.001 0 20 40 60 80 100 Reduction of Ulcers Disappearance of Ulcers Early combined immunosuppression (top-down; n=66) Conventional management (step-up; n=67) D’Haens G, et al. Lancet. 2008;371:660-667.

2. 2 Mucosal Healing Predicts Sustained Clinical Remission in Early CD Simple endoscopic score 0 Simple endoscopic score 1-9 20 40 60 80 100 Patients, % 0 RemissionRemission, No Steroids Remission, No Steroids, No Flare Remission, No Steroids, No Flare, No Anti-TNF abb b a P <0.05; b P <0.01 (Fischer’s exact) Baert FJ, et al. Presented at Digestive Disease Week. May 17-22, 2008; San Diego, CA; #W1133. Patients in remission at years 3 and 4

3. 3 SONIC Mucosal Healing at Week 26 16.5 30.1 43.9 0 20 40 60 80 100 Patients, % P<0.001 P=0.023P=0.055 18/10928/9347/107 AZA + placebo IFX + placebo IFX+ AZA Sandborn WJ, et al. Presented at American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course. October 3-8, 2008; Orlando, FL.

4. 4 The MUSIC Trial Endoscopic Mucosal Lesion Healing With Certolizumab Pegol a CDEIS score<7; b CDAI score ≤150 points; c ≥4-point change in CDEIS score. CDAI, Crohn’s disease activity index; CDEIS, Crohn’s disease endoscopic index of severity; MUSIC, Endoscopic Mucosal Improvement in Patients with Active Crohn's Disease Treated With Certolizumab Pegol. Colombel J. Am J Gastroenterol. 2008;103:S-132(1107). 55.1 74.4 46.1 0 10 20 30 40 50 60 70 80 Remission and Response Rates, % Response, CDEIS c Remission, CDEIS a Remission, CDAI b Observed improvement in endoscopic and histologic lesions